Surya Pharmaceuticals Ltd. - Research Center
532516 SURYAPHARM Group (Z) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 14 | Mar ' 13 | Mar ' 12 | Mar ' 11 | Mar ' 10 | |
|---|---|---|---|---|---|
| Sales | 12.64 | 60.33 | 1,622.95 | 1,600.42 | 1,130.20 |
| Operating profit | -634.51 | -156.98 | -154.78 | 253.37 | 163.28 |
| Interest | 254.79 | 203.69 | 165.85 | 97.78 | 62.46 |
| Gross profit | -888.82 | -378.31 | -358.61 | 158.26 | 111.01 |
| EPS (Rs) | -35.85 | -15.51 | -13.44 | 4.94 | 5.17 |
Annual
results in details
| Mar ' 14 | Mar ' 13 | Mar ' 12 | Mar ' 11 | Mar ' 10 | |
|---|---|---|---|---|---|
| Other income | 0.47 | -17.64 | -37.98 | 2.67 | 10.19 |
| Stock adjustment | 585.91 | 90.93 | 57.35 | -273.26 | -212.99 |
| Raw material | 41.55 | 91.93 | 1,597.15 | 1,504.25 | 1,100.37 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 1.96 | 8.85 | 40.91 | 40.36 | 27.88 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 17.73 | 25.61 | 82.31 | 75.70 | 51.67 |
| Provisions made | - | - | - | - | - |
| Depreciation | 62.63 | 62.47 | 34.62 | 26.55 | 20.89 |
| Taxation | -443.85 | -144.19 | -120.72 | 31.56 | 15.31 |
| Net profit / loss | -726.77 | -314.52 | -272.50 | 100.16 | 74.81 |
| Extra ordinary item | -219.17 | -17.93 | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 20.28 | 20.28 | 20.28 | 20.28 | 14.47 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | 1597.14 | 1597.14 | 1254.89 | 1254.89 | 86.92 |
| Agg.of non promotoholding (%) | 78.77 | 78.77 | 61.89 | 65.10 | 60.07 |
| OPM (%) | -5,021.80 | -260.21 | -9.54 | 15.83 | 14.45 |
| GPM (%) | -6,781.02 | -886.16 | -22.63 | 9.87 | 9.73 |
| NPM (%) | -5,544.70 | -736.73 | -17.19 | 6.25 | 6.56 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis